COMP <GO>
RDY vs SMMT // 10Y YIELD & FRED MACRO BETA
Dr. Reddy's Laboratories Ltd (NYSE) VS. Summit Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RDY 8
— SMMT 3
▲ 10Y YIELD & FRED MACRO BETA LEADER: RDY
LAST: $14.13 (-0.28%) • MKT CAP: $11.83B
macro-sensitivity
1.05
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
macro-sensitivity
0.97
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDY VS. SMMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RDY | SMMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | RDY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | -2.50% | +4.71 | RDY | /fcf-yield <GO> |
| Operating Margin | 13.90% | -36.30% | +50.20 | RDY | /operating-margins <GO> |
| Net Profit Margin | 10.90% | -29.80% | +40.70 | RDY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 11.00% | -4.40 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 26.00 | -22.26 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | RDY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.2 | 50.5 | +25.70 | RDY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.05 | 0.97 | +0.08 | RDY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 34.0x | -3.50 | RDY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.83B | $12.82B | -$992.5M | SMMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RDY REV | SMMT REV | RDY GROSS % | SMMT GROSS % | RDY FCF | SMMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $3.57B | — | — | — | -$323.6M |
| FY 2024 | — | $632.8M | — | — | — | -$142.2M |
| FY 2023 | — | $1.71B | — | — | — | -$76.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RDY // BETA 1.05
SMMT // BETA 0.97